AnaptysBio, Inc.

Contributing Author

Recent Articles by AnaptysBio, Inc.

Nov-04	Anaptys Announces Participation in November Investor Conferences ANAB GlobeNewswire
Nov-04	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire
Oct-29	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation ANAB GlobeNewswire
Oct-13	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 ANAB GlobeNewswire
Sep-29	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 ANAB GlobeNewswire
Sep-29	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 ANAB GlobeNewswire
Aug-27	Anaptys Announces Participation in September Investor Conferences ANAB GlobeNewswire
Aug-06	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire
Jun-03	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA ANAB GlobeNewswire
May-27	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 ANAB GlobeNewswire
May-05	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire